Non-Hodgkin LymphomaPhase 3SUNMONCT05171647
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
A Phase 3 study testing Mosunetuzumab, Polatuzumab vedotin and Tocilizumab in people with Non-Hodgkin Lymphoma, run by Hoffmann-La Roche at 51 sites in 13 countries.
Trial summary
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Hodgkin Lymphoma
- What is being tested?
- Mosunetuzumab, Polatuzumab vedotin and Tocilizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 208 participants
- Where
- 51 sitesin 13 countries
- Study dates
- 25 Apr 2022to 28 Feb 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); high-grade B-cell lymphoma (NOS or double/triple hit); transformed follicular lymphoma; follicular lymphoma Grade 3b
- Have disease relapsed or refractory to at least one prior systemic therapy for aggressive non-Hodgkin's lymphoma (aNHL)
- Participants who have received only one prior line of therapy must be ineligible for autologous stem cell transplant (ASCT)
- Measurable disease
- Adequate hepatic, hematologic, and renal function
- Estimated creatinine clearance (CrCl) ≥ 30 mL/min by Cockroft-Gault method or other institutional standard methods
- Negative HIV test at screening. Participants with a positive HIV test at screening are eligible provided that, prior to enrollment, they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count of at least 200 microliters, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
Who cannot join
- Pregnant or breast feeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab, 9 months after the final dose of polatuzumab vedotin, 12 months after the final dose of rituximab, 6 months after the final dose of gemcitabine, 9 months after the final dose of oxaliplatin, and 3 months after the final dose of tocilizumab, as applicable
- Inability to comply with protocol-mandated activity restrictions
- Prior treatment with mosunetuzumab or other CD-20-directed bispecific antibodies, or R-GemOx or Gem-Ox
- Prior treatment with polatuzumab vedotin, with the following exceptions: participants who have a documented response (partial response or complete response) to polatuzumab vedotin and an absence of PD within 12 months from the last dose of polatuzumab vedotin; participants who received up to 2 doses of a polatuzumab vedotin-containing regimen as bridging to CAR-T therapy, and either has a documented disease control (stable disease, partial response, or complete response), or were not assessed for response following treatment with polatuzumab vedotin
- Contraindication to any component of the study treatment
- Grade > 1 peripheral neuropathy
Show all 33Show fewer
- Participants with Grade > 1 persistent toxicity related to prior anti-lymphoma treatment (except for alopecia and anorexia, or other toxicities not considered a safety risk for the participant per investigator's judgment)
- Received anti-lymphoma treatments with monoclonal antibodies, radio-immunoconjugates or antibody-drug conjugates (ADCs) within 4 weeks before the first dose of study treatment
- Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
- Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
- ASCT within 100 days prior to the first study treatment administration
- Prior treatment with chimeric antigen receptor (CAR) T cell therapy within 30 days before the first study treatment administration
- Prior allogenic stem cell transplant (SCT)
- Have had a solid organ transplantation
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- History of confirmed progressive multifocal leukoencephalopathy
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombination antibody-related fusion proteins)
- History of other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of malignancies with a negligible risk of metastasis or death
- Currently have or have had a past history of central nervous system (CNS) involvement of lymphoma
- Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator, or with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications, are allowed
- Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
- Significant active pulmonary disease
- Participants with active symptoms of interstitial lung disease and/or pneumonitis, or those with a history of interstitial lung disease and/or pneumonitis within 6 months prior to the first dose of study treatment
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to the first study treatment administration
- Known or suspected chronic active Epstein-Barr virus (EBV) infection
- Recent major surgery within 4 weeks prior to the first study treatment administration
- Positive test results for chronic hepatitis B infection
- Acute or chronic hepatitis C virus (HCV) infection
- Have been administered a live, attenuated vaccine within 4 weeks before the first dose of study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
- Participants who have positive SARS-CoV-2 test within 7 days prior to enrollment (rapid antigen test result is acceptable)
- History of autoimmune disease
- Received investigational therapy, whether or not intended for lymphoma treatment, within 7 days prior to initiation of study treatment
- Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
Trial locations and contacts
51 sites in 13 countries.
51 sites in 13 countries
China6 sites
Sichuan Cancer Hospital
Chengdu, 610041
Fujian Medical University Union Hospital
Fuzhou, 350001
Cancer Center, Sun Yat-sen University of Medical Sciences
Guangzhou, 510060
Tianjin Cancer Hospital
Tianjin, 300060
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, 430030
Henan Cancer Hospital
Zhengzhou, 450008
Japan6 sites
Kyushu University Hospital
Fukuoka, 812-8582
Hokkaido University Hospital
Hokkaido, 060-8648
Tohoku University Hospital
Miyagi, 980-8574
Kindai University Hospital
Osaka, 589-8511
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550
Yamagata University Hospital
Yamagata, 990-9585
South Korea6 sites
Pusan National University Hospital
Busan, 49241
Chungnam National University Hospital
Daejeon, 35015
Seoul National University Hospital
Seoul, 03080
Severance Hospital, Yonsei University Health System
Seoul, 03722
Samsung Medical Center
Seoul, 06351
Yeouido St. Mary's Hospital
Seoul, 07345
Brazil5 sites
Hospital Erasto Gaertner
Curitiba, Paraná, 81520-060
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital das Clínicas FMRP-USP
Ribeirão Preto, São Paulo, 14048-900
Hospital Sao Jose
São Paulo, São Paulo, 01323-030
D'or Instituto de Pesquisa e Educação
São Paulo
Turkey (Türkiye)5 sites
Ankara University Medical Faculty
Ankara, 06100
Medipol Mega Üniversite Hastanesi Göztepe
Istanbul, 34214
Anadolu Health Center
Kocaeli, 41400
Dokuz Eylul Universitesi Tip Fakultesi
Lzmir, 35340
Ondokuz Mayis Univ. Med. Fac.
Samsun, 55139
United States4 sites
Ascension Seton Infusion Center
Austin, Texas, 78712
St. Luke's Hospital
Chesterfield, Missouri, 63017
City of Hope Cancer Center
Duarte, California, 91010
MD Anderson Cancer Center
Houston, Texas, 77030
Argentina4 sites
Hospital Aleman
Buenos Aires, 1118
Instituto Alexander Fleming
Buenos Aires, 1426
FUNDALEU
Buenos Aires, C1114AAN
Hospital Italiano de Buenos Aires
Ciudad Autonoma Buenos Aires, C1181ACH
Mexico4 sites
Instituto Nacional de Cancerologia
Distrito Federal, 14080
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
México
Superare Centro de Infusion S.A. de C.V.
Mexico City, Mexico CITY (federal District), 11550
Hospital Universitario Dr. Jose E. Gonzalez
Monterrey, Nuevo León, 64460
Canada3 sites
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2
Chum Hopital Notre Dame
Montreal, Quebec, H2L 4M1
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Thailand3 sites
Siriraj Hospital
Bangkok, 10700
Chiang Mai Uni Hospital
Chiang Mai, 50200
Srinagarind Hospital, Khon Kaen Uni
Khon Kaen, 40002
Israel2 sites
Soroka Medical Center
Beersheba, 8410101
Ichilov Sourasky Medical Center
Tel Aviv, 6423906
Peru2 sites
Instituto Regional de Enfermedades Neoplásicas del Sur
Arequipa, 5154
Oncosalud Sac
Lima, 41
About this study
Official title: A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
- Conditions
- Non-Hodgkin Lymphoma
- Being tested
- Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine
- Medical subject headings
- Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MosunetuzumabDrug
Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
Polatuzumab vedotinDrug
Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
TocilizumabDrug
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
RituximabDrug
Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
GemcitabineDrug
Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
OxaliplatinDrug
Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
| Study group | Role | What they receive |
|---|---|---|
| M+P (Arm A) | Experimental | Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days. Receives: Drug: Mosunetuzumab; Drug: Polatuzumab vedotin; Drug: Tocilizumab |
| R-GemOx (Arm B) | Active comparator | Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days. Receives: Drug: Rituximab; Drug: Gemcitabine; Drug: Oxaliplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.
Measured: Up to approximately 23.8 months
Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
PFS was defined as the time from randomization to first occurrence of disease progression (PD) or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.
Measured: Up to 32 months
Secondary outcomes (18)
ORR as Determined by the IRF, According to LRC Using PET-CT or CT Scans in ITT Population
ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.
Measured: Up to 32 months
ORR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans in ITT Population
ORR was defined as the percentage of participants with CR or PR, as determined by the investigator, per Lugano Response Criteria.
Measured: Up to approximately 58 months
Duration of Response (DoR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
DoR was defined as the time from first occurrence of documented PET-CT and/or CT-based objective response (OR) (CR/PR) to PD, or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.
Measured: Up to 32 months
DoR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans
DoR=time from first occurrence of documented PET-CT and/or CT-based objective response (OR) (CR/PR) to PD, or death from any cause, whichever occurred first, per investigator, per Lugano Response Criteria.
Measured: Up to approximately 58 months
Overall Survival (OS)
OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS.
Measured: Up to 32 months
PFS as Determined by the Investigator, According to LRC Using PET-CT or CT Scans
PFS was defined as the time from randomization to first occurrence of PD or death from any cause, whichever occurred first, as determined by the investigator, per Lugano Response Criteria.
Measured: Up to approximately 58 months
Complete Response Rate (CRR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
CRR was defined as the percentage of participants in whom CR was observed at any time during the study, based on PET-CT and/or CT scans, as determined by the IRF, per Lugano Response Criteria.
Measured: Up to approximately 58 months
CRR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans
CRR was defined as the percentage of participants in whom CR was observed at any time during the study, based on PET-CT and/or CT scans, as determined by the investigator, per Lugano Response Criteria.
Measured: Up to approximately 58 months
Duration of Complete Response (DOCR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
DOCR was defined as the time from first occurrence of a documented CR to PD, per IRF, per Lugano Response Criteria.
Measured: Up to 32 months
DOCR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans
DOCR=time from first occurrence of documented CR to PD, as determined by the investigator, per Lugano Response Criteria.
Measured: Up to approximately 58 months
Time to Deterioration in Physical Functioning (PF), as Measured by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire-Core 30 (EORTC QLQ-C30)
Time to deterioration in PF was defined as time from randomization to the first documentation of 10-point or more decrease, from baseline. EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea, vomiting, \& pain), global health status (GHS)/quality of life (QoL), \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning scales were scored on a 4-point scale, ranging from 1=Not at all to 4=Very much. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for a functioning scale indicated high/healthy level of functioning.
Measured: Up to approximately 58 months
Time to Deterioration in Fatigue Scale, as Measured by the EORTC QLQ-C30
Time to deterioration in fatigue was defined as time from randomization to the first documentation of 10-point or more decrease, from baseline. EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea, vomiting, \& pain), global health status (GHS)/quality of life (QoL), \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Fatigue scale was scored on a 4-point scale, ranging from 1=Not at all to 4=Very much. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for a fatigue scale indicated a high level of symptom severity.
Measured: Up to approximately 58 months
Time to Deterioration in Lymphoma Symptoms, as Measured by Functional Assessment of Cancer Therapy- Lymphoma Questionnaire (FACT- Lym LymS)
Time to deterioration in lymphoma-specific symptoms was defined as the time from randomization to the first documentation of a 3-point or more decrease, from baseline. FACT-Lym is a cancer-specific scale used to assess health-related QoL aspects relevant to participants with lymphoma. The full measure consists of the FACT-G physical, social/family, emotional, and functional well-being scales (27 items), as well as lymphoma-specific symptoms subscale (LymS). The FACT-Lym Lyms consists of 15 items scored from 0-4, where 0="Not at all" and 4="very much". Scale score ranges from 0 to 60, where a high score indicated a better QoL.
Measured: Up to approximately 58 months
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Measured: Up to approximately 58 months
Number of Participants With Cytokine Release Syndrome (CRS) With Severity Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.
Measured: Up to approximately 58 months
Number of Participants With Dose Interruptions, Dose Reductions and Study Treatment Discontinuation Due to AEs
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention. Participants who had dose interruptions or modifications or who discontinued study treatment due to AEs will be reported here.
Measured: Up to approximately 58 months
Dose Intensity of Mosunetuzumab
Measured: Up to approximately 58 months
Change From Baseline in Peripheral Neuropathy (PN), as Measured by the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)
The FACT/GOG-Ntx is an 11-item patient-reported outcome that measures polatuzumab vedotin-induced PN. The scale contains 4 subscales to assess sensory neuropathy (4 items), hearing neuropathy (2 items), motor neuropathy (3 items), and dysfunction associated with neuropathy (2 items), which can be summed to create a total score. Each item is scored on a 5-point response scale that ranges from 0=not at all to 4=very much. The possible range for the scores is 0-44, with higher scores indicating more extreme neuropathy.
Measured: Up to approximately 58 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2021
- Study start25 Apr 2022
- Primary completion17 Feb 2025
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Non-Hodgkin LymphomaStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 208 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05171647
- Sponsor's protocol ID
- GO43643
- Acronym
- SUNMO
- Status last verified
- Aug 2026
- First submitted
- 6 Dec 2021
- Last updated
- 5 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Publications
Maruyama D, Goto H, Kumode T, Aizawa K, Fukuhara N, Westin JR, Kim WS, Mori C, Imaizumi T, Kato K. Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. Int J Clin Oncol. 2026 Aug;31(8):1547-1556. doi: 10.1007/s10147-026-03042-x. Epub 2026 Jun 15.
PubMed 42298056Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah N, Assouline S, Olszewski AJ, Naik S, Ghosh N, Pham S, Wei MC, Batlevi C, To I, Ead W, Makadia S, Penuel E, Jing J, Budde LE. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. Am J Hematol. 2026 Sep;101(9):2177-2189. doi: 10.1002/ajh.70403. Epub 2026 Jun 12.
PubMed 42283231Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. J Clin Oncol. 2025 Dec 20;43(36):3799-3811. doi: 10.1200/JCO-25-01957. Epub 2025 Oct 2.
PubMed 41037766